gpt-dict.com

Magnolia Bark Extract for Sleep Quality

Verdict: Insufficient Evidence

Across 3 PubMed studies, the evidence for Magnolia Bark Extract in Sleep Quality grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.42
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
78%
Broadly consistent
Evidence level
E7
Single small RCT

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.418
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABAA receptor in mice
PMID: 22537192 2012 Animal Study n = 84
Finding: At 20 mg/kg honokiol shortened NREM sleep latency and increased NREM sleep ~3.8-fold over 4h without altering NREM EEG delta power (p<0.01).
Government Effect size: [object Object]
View on PubMed
Oral Delivery of Honokiol Microparticles for Nonrapid Eye Movement Sleep
PMID: 30652875 2019 Animal Study
Finding: Oral honokiol microparticles promoted NREM sleep in mice, supporting GABAA-mediated sleep mechanism via an oral route.
🟠 Limited quality
View on PubMed
Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial
PMID: 18426577 2008 RCT (double-blind) n = 40
Finding: Sleep quality and latency were NOT significantly changed by Relora vs placebo (anxiety reduced; 26/40 completers).
🟠 Limited quality ⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
The claims on your website establish that these products are drugs under section 201(g)(1) of the FD&C Act ... because they are intended for use in the cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body. source↗
L4d TW TFDA / 衛福部
Not addressed
厚朴收載於《臺灣中藥典》,屬中藥材;未列入衛福部中醫藥司公告之「可同時提供食品使用之中藥材」清單。 source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-sleep-quality-INT-magnolia-bark-001 繁體中文版 →